Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCD-044 in moderate to severe plaque psoriasis
NCT04566666Phase 2Completed
- Sponsor
- Sun Pharma
- Start
- Mar 2021
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of vibozilimod in plaque psoriasis (4 arms), sponsored by Sun Pharma. Primary endpoint: Proportion of Subjects With at Least 75% Improvement in Psoriasis Area and Severity Index at 16 weeks. Started Mar 2021; status: completed.
02
Drugs
vibozilimod
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04566666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04566666.